A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors

Pallavi Prakash Chaurasia 1, Sagar Dholariya 2, Fenilkumar Kotadiya 3, Milav Bhavsar 4

Abstract

Diabetes mellitus is a chronic disease that affects multiple organs and exhibits significant complications. The major outcomes of prolonged hyperglycemia are nephropathy, retinopathy, neuropathy, and cardiovascular events due to the glycation of lipids and proteins. To ensure a healthy lifestyle for diabetic patients, a treatment that delays the complications and simultaneously protects multiple organs is required. Sodium-glucose cotransporter inhibitors (SGLT2) inhibit the reabsorption of glucose from the kidney and shows promising benefits in renal and heart diseases. The major SGLT receptors are SGLT1 and SGLT2. Various trials are conducted to conclude their efficacy and show nephroprotective and cardioprotective roles independent of diabetic status. The FDA-approved SGLT2 inhibitors are empagliflozin (Jardiance®), canagliflozin (Invokana®), and dapagliflozin (Farxiga®), which are primarily used in type 2 diabetes mellitus (T2DM). They show a reduced rate of hospitalization for heart failure, cardiovascular disease mortality, all-cause mortality, and progression of diabetic kidney disease. It also shows improvement in the glycemic index; therefore, it is protective against the complications of diabetes irrespective of insulin release, thus avoids hypoglycemia. This review summarizes the data from the clinical trials that support the efficacy of SGLT2 inhibitors in reducing the risks of cardiovascular and renal outcomes in patients with T2DM.

Introduction And Background

Type 2 diabetes mellitus (T2DM) is one of the most prevalent diseases. It is now estimated that nearly 387 million people have diabetes globally, and deaths from diabetes are projected to increase 50% worldwide by 2025 [1]. The sedentary lifestyle and unhealthy eating habits are contributing to the increased prevalence of diabetes mellitus. T2DM is a multifactorial progressive disease and is caused by genetic, environmental, dietary, metabolic, and sedentary lifestyles. Management of diabetes mellitus requires a drug with high efficiency and a lower risk of hypoglycemia.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a new class of hypoglycemic drugs with promising health benefits. These drugs inhibit the reabsorption of glucose from the kidney; thus, they increase glycosuria, improve the glycemic index without affecting insulin release, and avoid hypoglycemia. SGLT receptors present in the luminal surface of epithelial cells are of low capacity; high-affinity glucose-sodium cotransporters reabsorb the filtered glucose against a concentration gradient [1-3]. The most important SGLT receptors are SGLT1 and SGLT2 receptors. Type 1 receptors are present in the small intestine and late proximal convoluted tubules and are responsible for the reabsorption of 10% of filtered glucose, while SGLT2 receptors are responsible for 90% glucose reabsorption from early proximal convoluted tubules, the main target of antidiabetic therapy [4-6]. The renal threshold for glucose is 180 mg/dl in the normoglycemic state, but in diabetes, it may reach up to 200-240 mg/dl and may exacerbate hyperglycemia. Studies show the increased expression of SGLT2 receptors, SGLT1 proteins, and mRNA in diabetic kidneys, thus increasing the reabsorption of glucose [7-11]. The US Food and Drug Administration (FDA) first approved the use of SGLT2 inhibitors in 2015 for patients with T2DM, and the first study was published in 2016, which demonstrated their beneficial effects in terms of delaying diabetic kidney disease (DKD) progression [12]. The class of SGLT2 inhibitors approved by the FDA in T2DM includes canagliflozin (Invokana®), dapagliflozin (Farxiga®), and empagliflozin (Jardiance®) [13].

In this review, we summarize the cardiac and renal benefits of SGLT2 inhibitors in T2DM based on the results of major randomized controlled trials and previously conducted studies. Figure 1 demonstrates various mechanisms responsible for the beneficial effects of SGLT2 inhibitors.
We systematically searched PubMed, Scopus, Web of Science, Google Scholar, ClinicalTrials.gov, and other databases for eligible articles using appropriate search words. We extracted data from placebo-controlled randomized controlled trials, original articles, meta-analyses, and systematic reviews that reported cardiovascular, renal, and other positive outcomes of SGLT2 inhibitors in individuals with T2DM. The screening of the articles is carried out by abstract screening and full-text reading to confirm the eligibility. The full text of references within the primary studies was also reviewed and included in the final study as needed. Out of 120 searched articles, a total of 25 articles were included in the final review after removing duplicates of studies, non-randomized trials, studies measuring other perspectives, and studies showing no outcome of interest. The detailed search strategy of the database is shown in Figure 2. The endpoint of the study was the composite cardiovascular (CV) outcomes, CV mortality, all-cause mortality, nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure. The renal composite outcome, albuminuria, and effects of estimated glomerular filtration rate (eGFR) were also studied.

**FIGURE 1: Mechanism of SGLT2 inhibitors**

ATP, Adenosine triphosphate. SGLT, sodium-glucose cotransporter.
Review

The major trials including empagliflozin and canagliflozin are Empagliflozin Cardiovascular Outcome Event Trial-Removing Excess Glucose (EMPA-REG OUTCOME) and Canagliflozin Cardiovascular Assessment Study (CANVAS) program, respectively, in T2DM patients. These trials show improvement in cardiovascular disease (CVD) and renal outcomes among 17,000 participants with T2DM [12,14-17]. The participants were randomly allocated to the placebo or empagliflozin group. The empagliflozin group demonstrated remarkable lower incidents of hospitalization for heart failure (35% relative risk reduction), CVD mortality (38% relative risk reduction), and death from any cause (32% relative risk reduction) in contrast to the placebo group [14]. The reduced rates were sustained among more than 2000 participants with an eGFR of less than 60 mL/min/1.73 m² and macroalbuminuria [15,18]. As compared to placebo, there is a 39% relative risk reduction in the new onset or worsening nephropathy in the empagliflozin group (13% vs. 19%, P < 0.001) [12,18].

The CANVAS program consolidated data from two CVD outcome trials, which included 10,000 participants with T2DM, allocated to either canagliflozin or placebo groups, and followed for an average of 3.6 years [17]. In comparison to the placebo, the primary composite outcome occurred in lower rates among canagliflozin takers in terms of CVD mortality, nonfatal myocardial infarction, and nonfatal stroke (14% relative risk reduction, P < 0.001). There is a 27% reduction in progression to albuminuria as well as 40% alleviation in the composite kidney disease outcomes that include 40% eGFR decline, kidney replacement therapy (KRT), or death from renal disease among the canagliflozin group against placebo [17]. The beneficial outcomes were persistent across the various stages of kidney function (eGFR: 30-45, 45-60, 60-90, and >90 mL/min/1.73 m²) though canagliflozin showed greater benefits on fatal/nonfatal strokes in eGFR < 60 mL/min/1.73 m² (hazard ratio: 0.56 in the 45-60 mL/min/1.73 m² group and 0.32 in the 50-45 mL/min/1.73 m² group vs.
Other clinical trials were Canagliflozin and RenalEndpoints in Diabetes With EstablishedNephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin andPrevention of Adverse Outcomes inChronic Kidney Disease (DAPA-CKD). These trials were designed to evaluate the effectiveness ofcanagliflozin or dapagliflozin on composite primary outcomes, which includes end-stage renal disease(ESKD), doubling of serum creatinine, 50% sustained decline in eGFR, and renal or CVD mortality inparticipants diagnosed with diabetic kidney disease (DKD) [20]. A total of 4401 participants were followed for amean duration of 2.62 years in the CREDENCE trial. The end result of the CREDENCE trial illustrated a 30%reduction in the relative risk of the primary outcome with the use of canagliflozin as compared to the placebo group, with incident rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio: 0.70;95% confidence interval (CI): 0.59-0.82; P = 0.00001). Also, there was a 34% reduction in the relative risk(hazard ratio: 0.66; 95% CI: 0.53-0.81; P < 0.001) of the renal-specific outcome of ESKD, a doubling of thecreatinine level, or renal-related mortality. The reduction in the relative risk of ESKD by 32% (hazard ratio,0.68; 95% CI, 0.54-0.86; P = 0.002) was also noted. The use of canagliflozin also revealed a risk reduction incardiovascular death, myocardial infarction, or stroke (hazard ratio: 0.80; 95% CI: 0.67-0.95; P = 0.01) andhospitalization for heart failure (hazard ratio: 0.61; 95% CI: 0.47-0.80; P < 0.001) [21].

Another trial evaluated the prevention of adverse outcomes in CKD patients taking dapagliflozin (eGFR 25-75 mL/min/1.73 m² and Urine Albumin Creatinine Ratio [UACR] > 200 mg/g) and in those with and withoutT2DM [22]. The primary outcome includes a composite kidney outcome (>50% sustained decline in eGFR,ESKD) or renal or cardiovascular mortality. As it demonstrated benefits in the dapagliflozin group, the trialwas terminated early; however, full results have not been released [23]. In the Dapagliflozin and Preventionof Adverse Outcomes in Heart Failure (DAPA-HF) trial, dapagliflozin showed a reduction in cardiovasculardeaths by 26% along with benefits in heart failure (hospitalization or an urgent visit resulting in intravenoustherapy for heart failure). This study evaluates the benefits of SGLT2i in patients with ejection fraction < 40%with or without T2DM [24]. The results of clinical trials are summarized in Table 1.
| Clinical Trials             | Drug       | Primary Outcome                  | Secondary Outcome                      |
|----------------------------|------------|----------------------------------|----------------------------------------|
|                            |            |                                  | All-Cause Mortality | Hospitalization for Heart Failure | CV Mortality |
| Empa-REG Outcome [14]      | Empagliflozin | MACE: HR 0.86; 95% CI: 0.74-0.99 | HR 0.68; 95% CI: 0.57-0.82 | HR 0.65; 95% CI: 0.50-0.85 | HR 0.62; 95% CI: 0.49-0.77 |
| (n = 7020)                 |            |                                  | HR 0.86; 95% CI: 0.68-0.99 | HR 0.67; 95% CI: 0.52-0.87 | HR 0.87; 95% CI: 0.72-1.06 |
| CANVAS [17] (n = 10,142)   | Canagliflozin | MACE: HR 0.86; 95% CI: 0.75-0.97 | HR 0.87; 95% CI: 0.74-1.01 | HR 0.84; 95% CI: 0.67-0.85 | HR 0.84; 95% CI: 0.67-0.85 |
| CREDENCE [21] (n = 4401)   | Canagliflozin | Doubled creatinine: HR 0.60; 95% CI: 0.48-0.76 | HR 0.83; 95% CI: 0.68-1.02 | HR 0.80; 95% CI: 0.47-0.80 | HR 0.80; 95% CI: 0.67-0.95 |
| DAPA-CKD [42] (n = 4304)   | Dapagliflozin | Decline of ≥50% in eGFR: HR 0.53; 95% CI: 0.42–0.67 | HR 0.69; 95% CI: 0.53–0.88 | Nephropathy: HR 0.56; 95% CI: 0.45–0.68 | HR 0.71; 95% CI: 0.55–0.92 |
|                            |            | New ESKD: HR 0.64; 95% CI: 0.50–0.82 | CV mortality: HR 0.81; 95% CI: 0.58–1.12 |                                      |                     |
| DAPA-HF [24] (n = 4744)    | Dapagliflozin | Worsening HF: HR 0.74; 95% CI: 0.65-0.85 | HR 0.83; 95% CI: 0.59-0.83 | Nephropathy: HR 0.71; 95% CI: 0.44–1.16 | HR 0.75; 95% CI: 0.65–0.85 |
|                            |            | CV mortality: HR 0.82; 95% CI: 0.69-0.98 | CV mortality: HR 0.71-0.97 |                                      |                     |

**TABLE 1: Primary and secondary outcomes of clinical trials**

MACE, Major adverse cardiovascular events; HF, heart failure; HR, hazard ratio; CI, confidence interval; CV, cardiovascular; CKD, chronic kidney disease; ESKD, end-stage kidney disease (eGFR < 15 mL/min/1.73 m²); CANVAS, Canagliflozin Cardiovascular Assessment Study; DAPA, dapagliflozin; CREDENCE, Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluation; Empa-REG Outcome, Empagliflozin Removing Excess Glucose (EMPA-REG) outcome; HHF, hospitalization for heart failure.

The nephroprotective role of these drugs is explained by various mechanisms. The most important is the opposition of glomerular hyperfiltration, which prevents glomerular capillary hypertension, thus renal injury [25]. Increased urinary glucose load causes increased expression of SGLT2 receptors, thus increased reabsorption of glucose and sodium into the tubules, which leads to decreased concentration of sodium reaching macula densa due to which there is a reduction in ATP breakdown and production of adenosine. Adenosine is a strong vasoconstrictor, but its deficiency leads to vasodilation of afferent arterioles, thus hyperfiltration. The altered tubuloglomerular feedback system is responsible for aggravated renal injury [26]. With the use of SGLT2 inhibitors, there is increased sodium carried to macula densa, resulting in increased adenosine production and afferent vasoconstriction, thus a reduction in renal plasma flow and glomerular filtration rate (GFR) and restoration of the tubule-glomerular feedback.

A study explored the effect of empagliflozin in T1D and glomerular hyperfiltration as a decrease in measured GFR (inulin clearance) by 33 mL/min/1.73 m² (172 ± 25 mL/min/1.73 m² to 139 ± 25 mL/min/1.73 m²) in conjunction with decreased plasma flows to the kidney and increased kidney vascular resistance. This effect was only observed in patients with diabetes with glomerular hyperfiltration and not in normal glomerular pressure [27]. Some studies also showed a decrease in the hyperglycemia-mediated generation of reactive oxygen species, thus having additional protective anti-inflammatory and antifibrotic effects [28,29]. Clinical trials show reductions in HbA1c with empagliflozin and dapagliflozin in patients with eGFR > 45 and < 60 mL/min/1.73 m² but not in patients with eGFR < 40 mL/min/1.73 m² [30,31]. The analysis of the phase III empagliflozin trials and the CANVAS program also showed the beneficiary effects of weight loss in diabetic patients that were maintained with eGFR as low as 30 mL/min/1.73 m² [19,31]. Low fat may decrease...
albuminuria and glomerular hyperfiltration, which indirectly protects the diabetic kidney and further supports the renoprotective role of SGLT2 inhibitors [30,32]. Antihypertensive effects of SGLT2 inhibitors are believed to be attributed to natriuresis, weight loss, improved endothelial function, and vascular compliance [33-37]. Empagliflozin, dapagliflozin, and canagliflozin lower the systolic blood pressure by approximately 5 mmHg and diastolic blood pressure by approximately 2 mmHg while maintaining the magnitude of blood pressure reduction depending on eGFR [18,30-42].

The summary of the benefits of SGLT2 inhibitors of different body functions is demonstrated in Figure 3.

![Figure 3: Benefits of SGLT2 inhibitors]

**FIGURE 3: Benefits of SGLT2 inhibitors**

HbA1c, Glycated hemoglobin; SGLT, sodium-glucose cotransporter.

**Conclusions**

The SGLT2 inhibitors appear to play a promising role in preventing cardiac and renal disease and reducing overall mortality in diabetes patients. In addition, their use causes better glycemic control, a decrease in HbA1c levels, and a low risk of hypoglycemia. Furthermore, they decrease the relative risk of stroke, nonfatal myocardial infarction, and hypertension. More benefits include weight loss, delayed albuminuria, natriuresis, anti-inflammatory, and antioxidant properties. The clinical trials demonstrated the drug’s potential as a critical diabetes mellitus treatment and in helping to counter off its complications.

**Additional Information**

**Disclosures**

**Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**

1. Shubrook JH, Bokaie BB, Adkins SE: Empagliflozin in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2015, 9:5793-803. 10.2147/DDDT.S69926
2. Tripitt C, Cornell S: Canagliflozin treatment in patients with type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2015, 8:73-81. 10.4137/CMEDE.531526
3. Gerich JE: Role of the kidney in normal glucose homeostasis and in the hyperglycemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010, 27:136-42. 10.1111/j.1464-5491.2009.02894.x
4. Scheen AJ: Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2)
inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015, 75:53-59. 10.1007/s40265-014-0357-y

5. Fioretti P, Giacari A, Sesti G: Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol. 2015, 14:142. 10.1186/s12933-015-0297-x

6. Coady MJ, Wallendorf B, Lapointe Y: Characterization of the transport activity of SGLT2/MAPI7, the renal low-affinity Na+-glucose cotransporter. Am J Physiol Renal Physiol. 2017, 313:F467-74. 10.1152/ajprenal.00628.2016

7. Freitas HS, Anhê GF, Melo KF, Okamoto MM, Oliveira-Souza M, Bordin S, Machado UF: Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1 alpha expression and activity. Endocrinology. 2008, 149:717-24. 10.1210/en.2007-1008

8. Gallo LA, Ward MS, Forthoferingham AK, et al.: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016, 6:1-16. 10.1038/srep26428

9. Stearns AT, Balakrishnan A, Rhoads DB, Tavakkolizadeh A: Rapid upregulation of sodium-glucose transporter SGLT1 in response to intestinal sweet taste stimulation. Ann Surg. 2010, 251:865-71. 10.1097/SLA.0b013e318197e1f1

10. Rahmouni H, Thompson PW, Ward JM, Smith CD, Hong G, Brown I: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005, 54:5427-34. 10.2373/diabetes.54.12.5427

11. Norton L, Shannon CI, Fourcaudt M, et al.: Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab. 2017, 19:1522-6. 10.1111/dob.13003

12. Wanner C, Inzucchi SE, Lachin JM, et al.: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016, 375:523-54. 10.1056/NEJMoa1515920

13. Hsia OS, Grove O, Cefalu WT: An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017, 24:75-9. 10.1097/MEO.0000000000000311

14. Zinnman B, Wanner C, Lachin JM, et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056/NEJMoa1504720

15. Wanner C, Lachin JM, Inzucchi SE, et al.: Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018, 137:119-29. 10.1161/CIRCULATIONAHA.117.028268

16. Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pifarre E, George JT, Zinnman B: Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia. 2018, 61:1712-23. 10.1007/s00125-018-4644-9

17. Neal B, Perkovic V, Mahaffey KW, et al.: Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056/NEJMoa1619192

18. Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR: Sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. N Engl J Med. 2017, 377:644-57. 10.1056/NEJMoa1619192

19. Neuen BL, Ohkuma T, Neal B, et al.: Sodium-glucose co-transporter-2 and kidney function. Circulation. 2019, 138:1537-50. 10.1161/CIRCULATIONAHA.118.035901

20. Jardine MJ, Mahaffey KW, Neal B, et al.: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol. 2017, 46:462-72. 10.1055/s-0038-164633

21. Perkovic V, Jardine MJ, Neal B, et al.: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056/NEJMoa1811744

22. Heerspink HJ, Stefansson BV, Chertow GM, et al.: Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-Ckd) randomized controlled trial. Nephrol Dial Transplant. 2020, 35:274-82. 10.1093/ndt/gfz020

23. Kim SH, Chang TI, Mahaffey KW: A call for a new paradigm for diabetes care in the era of sodium-glucose cotransporter 2 inhibitors (SGLT2i). Cardiol Ther. 2020, 9:219-25. 10.1007/s40119-020-00190-7

24. McMurray JIV, Solomon SD, Inzucchi SE, et al.: Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056/NEJMoa1911503

25. Fioretto P, Zambo A, Rossato M, Busetto L, Vettor R: SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016, 39:S165-71. 10.2337/dc16-0007

26. Faulhaber-Walter R, Chen L, Oppermann M, et al.: Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury. J Am Soc Nephrol. 2008, 19:722-30. 10.1681/ASN.2007060721

27. Cherney DZ, Perkins BA, Soleymanlou N, et al.: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014, 129:587-97. 10.1161/CIRCULATIONAHA.115.055081

28. Dekkers CC, Petrovik S, Laverman GD, Cherney DZ, Garnevoort HT, Heerspink HJ: Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018, 20:1988-95. 10.1111/dob.13501

29. Ishibashi Y, Matsui T, Yamagishi S: Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016, 48:191-5. 10.1055/s-0035-1555791

30. Kohan DE, Fioretti P, Tang W, List JF: Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014, 85:962-71. 10.1038/ki.2013.359

31. Cherney DZ, Cooper ME, Tikkanen I, et al.: Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and Hba1c reductions with empagliflozin. Kidney Int. 2018, 95:231-44. 10.1016/j.kint.2017.06.017

32. Škrtic M, Cherney DZ: Sodium-glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy. Curr Opin Nephrol Hypertens. 2015, 24:96-103. 10.1097/HNH.0000000000000084
33. Luzardo L, Noboa O, Boggia J: Mechanisms of salt-sensitive hypertension. Curr Hypertens Rev. 2015, 11:14-21. 10.2174/1573402111666150530204136
34. Tanaka H, Takano K, Iijima H, et al.: Factors affecting canagliflozin-induced transient urine volume increase in patients with type 2 diabetes mellitus. Adv Ther. 2017, 34:436-51. 10.1007/s12325-016-0457-8
35. Heerspink HJL, de Zeeuw D, Wie L, Leslie B, List J: Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2015, 15:853-62. 10.1111/dom.12127
36. Cooper JN, Buchanich JM, Youk A, Brooks MM, Barinas-Mitchell E, Conroy MB, Sutton-Tyrrell K: Reductions in arterial stiffness with weight loss in overweight and obese young adults: potential mechanisms. Atherosclerosis. 2012, 223:485-90. 10.1016/j.atherosclerosis.2012.05.022
37. Cardoso CR, Ferreira MT, Leite NC, Salles GF: Prognostic impact of aortic stiffness in high-risk type 2 diabetic patients: the Rio de Janeiro type 2 diabetes cohort study. Diabetes Care. 2013, 36:3772-8. 10.2337/dc13-0506
38. Vasilakou D, Karagiannis T, Athanasiadou E, et al.: Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2015, 159:262-74. 10.7326/0003-4819-159-4-201508200-00007
39. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB: Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014, 8:262-75.e9. 10.1016/j.jash.2014.01.007
40. Liu XY, Zhang N, Chen R, Zhao JG, Yu P: Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015, 29:1295-303. 10.1016/j.jdiacomp.2015.07.011
41. Yang XP, Lai D, Zhong XY, Shen HP, Huang YL: Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014, 70:1149-58. 10.1007/s00228-014-1752-x
42. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al.: Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056/NEJMoa2024816